S&P 500   3,883.71 (-2.27%)
DOW   31,439.01 (-1.38%)
QQQ   282.83 (-3.63%)
AAPL   138.54 (-3.19%)
MSFT   255.97 (-1.80%)
FB   177.71 (-9.44%)
GOOGL   2,064.00 (-7.43%)
AMZN   2,062.60 (-4.12%)
TSLA   638.77 (-5.35%)
NVDA   160.95 (-4.75%)
BABA   82.50 (-5.42%)
NIO   14.67 (-8.31%)
AMD   91.49 (-3.77%)
CGC   4.93 (-5.01%)
MU   66.94 (-3.81%)
T   20.64 (-0.48%)
GE   72.41 (-4.04%)
F   12.29 (-4.21%)
DIS   100.23 (-5.29%)
AMC   10.57 (-8.72%)
PFE   52.86 (-0.04%)
PYPL   77.73 (-4.25%)
NFLX   178.49 (-4.77%)
S&P 500   3,883.71 (-2.27%)
DOW   31,439.01 (-1.38%)
QQQ   282.83 (-3.63%)
AAPL   138.54 (-3.19%)
MSFT   255.97 (-1.80%)
FB   177.71 (-9.44%)
GOOGL   2,064.00 (-7.43%)
AMZN   2,062.60 (-4.12%)
TSLA   638.77 (-5.35%)
NVDA   160.95 (-4.75%)
BABA   82.50 (-5.42%)
NIO   14.67 (-8.31%)
AMD   91.49 (-3.77%)
CGC   4.93 (-5.01%)
MU   66.94 (-3.81%)
T   20.64 (-0.48%)
GE   72.41 (-4.04%)
F   12.29 (-4.21%)
DIS   100.23 (-5.29%)
AMC   10.57 (-8.72%)
PFE   52.86 (-0.04%)
PYPL   77.73 (-4.25%)
NFLX   178.49 (-4.77%)
S&P 500   3,883.71 (-2.27%)
DOW   31,439.01 (-1.38%)
QQQ   282.83 (-3.63%)
AAPL   138.54 (-3.19%)
MSFT   255.97 (-1.80%)
FB   177.71 (-9.44%)
GOOGL   2,064.00 (-7.43%)
AMZN   2,062.60 (-4.12%)
TSLA   638.77 (-5.35%)
NVDA   160.95 (-4.75%)
BABA   82.50 (-5.42%)
NIO   14.67 (-8.31%)
AMD   91.49 (-3.77%)
CGC   4.93 (-5.01%)
MU   66.94 (-3.81%)
T   20.64 (-0.48%)
GE   72.41 (-4.04%)
F   12.29 (-4.21%)
DIS   100.23 (-5.29%)
AMC   10.57 (-8.72%)
PFE   52.86 (-0.04%)
PYPL   77.73 (-4.25%)
NFLX   178.49 (-4.77%)
S&P 500   3,883.71 (-2.27%)
DOW   31,439.01 (-1.38%)
QQQ   282.83 (-3.63%)
AAPL   138.54 (-3.19%)
MSFT   255.97 (-1.80%)
FB   177.71 (-9.44%)
GOOGL   2,064.00 (-7.43%)
AMZN   2,062.60 (-4.12%)
TSLA   638.77 (-5.35%)
NVDA   160.95 (-4.75%)
BABA   82.50 (-5.42%)
NIO   14.67 (-8.31%)
AMD   91.49 (-3.77%)
CGC   4.93 (-5.01%)
MU   66.94 (-3.81%)
T   20.64 (-0.48%)
GE   72.41 (-4.04%)
F   12.29 (-4.21%)
DIS   100.23 (-5.29%)
AMC   10.57 (-8.72%)
PFE   52.86 (-0.04%)
PYPL   77.73 (-4.25%)
NFLX   178.49 (-4.77%)

Compare Stocks

Enter up to ten stock symbols separated by a comma or space (ex. NVCR,GMED,TNDM,PEN,INSP).

Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NVCR
NovoCure
$73.57
-4.6%
$78.63
$56.51
$232.76
$7.69B0.88665,919 shs2,919 shs
GMED
Globus Medical
$65.29
-1.1%
$70.13
$57.21
$84.23
$6.63B1.11740,235 shs7,643 shs
TNDM
Tandem Diabetes Care
$67.22
-5.5%
$101.61
$67.03
$155.86
$4.30B0.66638,066 shs16,726 shs
PEN
Penumbra
$136.44
-4.2%
$186.32
$130.96
$293.20
$5.14B0.61246,712 shs2,141 shs
INSP
Inspire Medical Systems
$167.53
-5.4%
$221.57
$142.74
$286.29
$4.62B1.65300,775 shs845 shs

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NVCR
NovoCure
+3.19%+15.56%-2.69%-0.91%-57.38%
GMED
Globus Medical
+1.66%+2.96%-3.69%+0.26%-7.23%
TNDM
Tandem Diabetes Care
-1.18%-1.14%-32.54%-32.98%-17.03%
PEN
Penumbra
+0.37%+1.50%-23.72%-34.21%-44.16%
INSP
Inspire Medical Systems
+0.72%+8.24%-20.86%-19.49%-0.48%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionCommunity RankDividend StrengthCompany OwnershipEarnings & Valuation
NVCR
NovoCure
2.05 of 5 Stars
3.44.40.02.50.0
GMED
Globus Medical
2.71 of 5 Stars
3.54.70.04.21.3
TNDM
Tandem Diabetes Care
2.58 of 5 Stars
3.34.40.03.31.9
PEN
Penumbra
2.76 of 5 Stars
4.45.00.02.51.9
INSP
Inspire Medical Systems
2.19 of 5 Stars
3.44.40.02.50.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
NVCR
NovoCure
2.75
Buy$144.7596.75% Upside
GMED
Globus Medical
2.90
Buy$83.9128.52% Upside
TNDM
Tandem Diabetes Care
2.60
Buy$137.70104.85% Upside
PEN
Penumbra
2.88
Buy$264.4393.81% Upside
INSP
Inspire Medical Systems
2.86
Buy$298.8378.38% Upside

Current Analyst Ratings

Latest NVCR, GMED, TNDM, PEN, and INSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/17/2022
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$155.00 ➝ $130.00
5/17/2022
PEN
Penumbra
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$280.00 ➝ $220.00
5/16/2022
NVCR
NovoCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$115.00
5/13/2022
NVCR
NovoCure
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$125.00 ➝ $100.00
5/11/2022
GMED
Globus Medical
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$80.00 ➝ $75.00
5/11/2022
GMED
Globus Medical
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$80.00 ➝ $70.00
5/5/2022
TNDM
Tandem Diabetes Care
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$142.00 ➝ $130.00
5/5/2022
TNDM
Tandem Diabetes Care
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$170.00 ➝ $120.00
5/4/2022
PEN
Penumbra
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$321.00 ➝ $265.00
5/4/2022
INSP
Inspire Medical Systems
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$305.00 ➝ $310.00
5/3/2022
PEN
Penumbra
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 5/24/2019 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
NVCR
NovoCure
$535.03M14.38N/AN/A$4.17 per share17.64
GMED
Globus Medical
$958.10M6.92$2.81 per share23.27$17.58 per share3.71
TNDM
Tandem Diabetes Care
$702.80M6.12$0.48 per share140.94$6.84 per share9.83
PEN
Penumbra
$747.59M6.88$1.10 per share124.46$25.46 per share5.36
INSP
Inspire Medical Systems
$233.39M19.81N/AN/A$8.16 per share20.53

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
NVCR
NovoCure
-$58.35M-$0.56N/AN/AN/A-10.94%-14.21%-5.22%8/4/2022 (Estimated)
GMED
Globus Medical
$149.19M$1.3648.0127.202.7614.77%11.95%10.69%8/3/2022 (Estimated)
TNDM
Tandem Diabetes Care
$15.57M$0.08840.3661.11N/A0.80%1.64%0.74%8/3/2022 (Estimated)
PEN
Penumbra
$5.28M-$0.17N/A110.93N/A-0.83%1.97%1.45%8/8/2022 (Estimated)
INSP
Inspire Medical Systems
-$42.04M-$1.56N/AN/AN/A-16.20%-19.02%-14.97%8/2/2022 (Estimated)

Latest NVCR, GMED, TNDM, PEN, and INSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/10/20223/31/2022
GMED
Globus Medical
$0.47$0.42-$0.05N/A$232.88 million$230.55 million    
5/4/2022Q1 2022
TNDM
Tandem Diabetes Care
N/A-$0.23-$0.23-$0.23$168.21 million$175.91 million      
5/3/20223/31/2022
PEN
Penumbra
$0.04-$0.01-$0.05N/A$195.39 million$203.90 million      
5/3/20223/31/2022
INSP
Inspire Medical Systems
-$0.73-$0.61+$0.12N/A$64.17 million$69.40 million    
4/28/20223/31/2022
NVCR
NovoCure
-$0.19-$0.04+$0.15N/A$134.29 million$137.50 million      
2/24/2022Q4 2021
NVCR
NovoCure
-$0.10-$0.25-$0.15-$0.25$134.49 million$133.20 million    
(Earnings results data provided by Zacks Investment Research)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
NVCR
NovoCure
N/AN/AN/AN/AN/A
GMED
Globus Medical
N/AN/AN/AN/AN/A
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A
PEN
Penumbra
N/AN/AN/AN/AN/A
INSP
Inspire Medical Systems
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
NVCR
NovoCure
1.29
8.46
8.23
GMED
Globus Medical
N/A
6.48
4.68
TNDM
Tandem Diabetes Care
0.64
6.21
5.60
PEN
Penumbra
0.03
5.31
3.20
INSP
Inspire Medical Systems
0.06
6.08
5.57

Ownership

Institutional Ownership

CompanyInstitutional Ownership
NVCR
NovoCure
78.4%
GMED
Globus Medical
67.19%
TNDM
Tandem Diabetes Care
94.62%
PEN
Penumbra
80.5%
INSP
Inspire Medical Systems
93.98%

Insider Ownership

CompanyInsider Ownership
NVCR
NovoCure
5.07%
GMED
Globus Medical
24.75%
TNDM
Tandem Diabetes Care
2.2%
PEN
Penumbra
7.5%
INSP
Inspire Medical Systems
5%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
NVCR
NovoCure
1,167104.59 million99.28 millionOptionable
GMED
Globus Medical
2,400101.56 million76.42 millionOptionable
TNDM
Tandem Diabetes Care
2,00063.96 million62.56 millionOptionable
PEN
Penumbra
3,80037.68 million34.85 millionOptionable
INSP
Inspire Medical Systems
48527.59 million26.21 millionOptionable

NVCR, GMED, TNDM, PEN, and INSP Headlines

SourceHeadline
Inspire Medical Systems (NYSE:INSP) Lowered to "D+" at TheStreetInspire Medical Systems (NYSE:INSP) Lowered to "D+" at TheStreet
marketbeat.com - May 24 at 7:53 AM
Zacks: Brokerages Anticipate Inspire Medical Systems, Inc. (NYSE:INSP) Will Announce Quarterly Sales of $78.70 MillionZacks: Brokerages Anticipate Inspire Medical Systems, Inc. (NYSE:INSP) Will Announce Quarterly Sales of $78.70 Million
marketbeat.com - May 23 at 5:56 AM
Inspire Medical Systems, Inc. (NYSE:INSP) Given Average Recommendation of "Buy" by BrokeragesInspire Medical Systems, Inc. (NYSE:INSP) Given Average Recommendation of "Buy" by Brokerages
marketbeat.com - May 15 at 5:15 AM
Inspire Medical Systems (NYSE:INSP) and PROCEPT BioRobotics (NASDAQ:PRCT) Critical ContrastInspire Medical Systems (NYSE:INSP) and PROCEPT BioRobotics (NASDAQ:PRCT) Critical Contrast
americanbankingnews.com - May 12 at 2:20 AM
STRATA Skin Sciences (NASDAQ:SSKN) vs. Inspire Medical Systems (NYSE:INSP) Critical ReviewSTRATA Skin Sciences (NASDAQ:SSKN) vs. Inspire Medical Systems (NYSE:INSP) Critical Review
americanbankingnews.com - May 12 at 1:34 AM
Inspire Medical Systems, Inc. to Present at the USB Global Healthcare Conference 2022Inspire Medical Systems, Inc. to Present at the USB Global Healthcare Conference 2022
nz.finance.yahoo.com - May 11 at 8:17 AM
Inspire Medical Systems, Inc. to Present at the USB Global Healthcare Conference 2022Inspire Medical Systems, Inc. to Present at the USB Global Healthcare Conference 2022
finance.yahoo.com - May 11 at 8:17 AM
Piper Sandler Raises Inspire Medical Systems (NYSE:INSP) Price Target to $310.00Piper Sandler Raises Inspire Medical Systems (NYSE:INSP) Price Target to $310.00
americanbankingnews.com - May 8 at 5:02 AM
Q2 2022 Earnings Estimate for Inspire Medical Systems, Inc. Issued By SVB Leerink (NYSE:INSP)Q2 2022 Earnings Estimate for Inspire Medical Systems, Inc. Issued By SVB Leerink (NYSE:INSP)
americanbankingnews.com - May 7 at 1:40 AM
Oversold Conditions For Inspire Medical Systems (INSP)Oversold Conditions For Inspire Medical Systems (INSP)
nasdaq.com - May 5 at 6:33 PM
Inspire Medical Systems (NYSE:INSP) Price Target Increased to $310.00 by Analysts at Piper SandlerInspire Medical Systems (NYSE:INSP) Price Target Increased to $310.00 by Analysts at Piper Sandler
marketbeat.com - May 4 at 7:28 AM
Inspire Medical Systems, Inc. (INSP) CEO Timothy Herbert on Q1 2022 Results - Earnings Call TranscriptInspire Medical Systems, Inc. (INSP) CEO Timothy Herbert on Q1 2022 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 10:57 PM
Inspire Medical Systems Q1 Loss Widens; But Lifts FY Revenue OutlookInspire Medical Systems Q1 Loss Widens; But Lifts FY Revenue Outlook
nasdaq.com - May 3 at 10:57 PM
Inspire Medical Systems, Inc. Announces First Quarter 2022 Financial Results and Updates 2022 OutlookInspire Medical Systems, Inc. Announces First Quarter 2022 Financial Results and Updates 2022 Outlook
finance.yahoo.com - May 3 at 5:56 PM
Headwaters Capital’s Top Contributor: Inspire Medical Systems (INSP)Headwaters Capital’s Top Contributor: Inspire Medical Systems (INSP)
finance.yahoo.com - May 3 at 7:55 AM
Inspire Medical Systems Q1 2022 Earnings PreviewInspire Medical Systems Q1 2022 Earnings Preview
seekingalpha.com - May 2 at 8:44 PM
Inspire Medical Systems invests in EnsoData and OgnomyInspire Medical Systems invests in EnsoData and Ognomy
massdevice.com - April 28 at 1:09 PM
Sleeping giant: Buffalo-based Ognomy scores corporate partner/investorSleeping giant: Buffalo-based Ognomy scores corporate partner/investor
finance.yahoo.com - April 28 at 1:09 PM
Sleep apnea solutions provider Inspire Medical invests in two private companiesSleep apnea solutions provider Inspire Medical invests in two private companies
seekingalpha.com - April 27 at 8:40 PM
Inspire Medical Systems, Inc. Announces Investments in EnsoData and OgnomyInspire Medical Systems, Inc. Announces Investments in EnsoData and Ognomy
finance.yahoo.com - April 27 at 8:40 PM
Inspire Medical Systems, Inc. to Present at the BofA Securities 2022 Healthcare ConferenceInspire Medical Systems, Inc. to Present at the BofA Securities 2022 Healthcare Conference
finance.yahoo.com - April 27 at 10:40 AM
Earnings Preview: Inspire Medical Systems (INSP) Q1 Earnings Expected to DeclineEarnings Preview: Inspire Medical Systems (INSP) Q1 Earnings Expected to Decline
finance.yahoo.com - April 26 at 6:59 PM
TransPerfects GlobalLink Vasont Inspire CCMS Selected by American Health Plans to Support Open Enrollment Document RolloutTransPerfect's GlobalLink Vasont Inspire CCMS Selected by American Health Plans to Support Open Enrollment Document Rollout
finance.yahoo.com - April 26 at 1:10 AM
TransPerfect’s GlobalLink Vasont Inspire CCMS Selected by American Health Plans to Support Open Enrollment Document RolloutTransPerfect’s GlobalLink Vasont Inspire CCMS Selected by American Health Plans to Support Open Enrollment Document Rollout
finance.yahoo.com - April 25 at 8:10 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.